Sofen B, Prado G, Emer J
Rush University Medical Center, Chicago, Il, USA.
Florida International University, Herbert Wertheim College of Medicine, Miami, FL, USA.
Skin Therapy Lett. 2016 Jan;21(1):1-7.
Dyschromia is a leading cause for cosmetic consultation, especially in those with diverse skin types (mixture of ethnicities) and with the rise of non-core and untrained physicians performing cosmetic procedures. Melasma and post-inflammatory hyperpigmentation (PIH) account for the majority of cases and are characterized by pigmented macules and patches distributed symmetrically in sun-exposed areas of the forehead, cheeks, and chin in melasma, and irregularly in areas of inflammation or an inciting traumatic event with PIH. Treatment is challenging and focused on a variety of mechanisms to stop, hinder, and/or prevent steps in the pigment production (melanocytic hyperactivity) process, breaking down deposited pigment for internal removal or external release, exfoliating cells to enhance turnover, and decreasing inflammation. Topical lightening therapy in combination with sun protection is essential for potential improvement. The most commonly prescribed and researched topical lightening agents are hydroquinone (HQ), azelaic acid (AzA), and retinoids - although only HQ and a triple combination cream (Tri-Luma®; fluocinolone acetonide 0.01%, HQ 4%, tretinoin 0.05%) are US FDA-approved for "bleaching of hyperpigmented skin" (HQ) and "melasma" (Tri-Luma®). Numerous non-HQ brightening/lightening agents, including antioxidant and botanical cosmeceuticals, have recently flooded the market with improvements that claim less irritant potential, as well as avoiding the stigmata associated with HQ agents such as carcinogenesis and cutaneous ochronosis. Combining topical therapy with procedures such as chemical peels, intense pulsed light (IPL), fractional non-ablative lasers or radiofrequency, pigment lasers (microsecond, picosecond, Q-switched), and microneedling, enhances results. With proper treatment, melasma can be controlled, improved, and maintained; alternatively, PIH can be cured in most cases. Herein, we review treatments for both conditions and provide an opinion on proper management for enhanced results.
色素沉着异常是美容咨询的主要原因,尤其是在皮肤类型多样(不同种族混合)的人群中,以及随着非核心和未经培训的医生进行美容手术的增加。黄褐斑和炎症后色素沉着(PIH)占大多数病例,黄褐斑的特征是色素沉着斑对称分布在前额、脸颊和下巴的阳光暴露区域,而PIH则不规则地分布在炎症区域或引发创伤事件的部位。治疗具有挑战性,重点在于通过多种机制来阻止、阻碍和/或预防色素生成(黑素细胞活性亢进)过程中的步骤,分解沉积的色素以便内部清除或外部排出,使细胞脱落以促进更新,并减轻炎症。局部美白疗法与防晒相结合对于潜在的改善至关重要。最常用且研究最多的局部美白剂是氢醌(HQ)、壬二酸(AzA)和维甲酸——尽管只有HQ和一种三联组合乳膏(Tri-Luma®;醋酸氟轻松0.01%,HQ 4%,维甲酸0.05%)获得美国食品药品监督管理局(FDA)批准用于“色素沉着皮肤的漂白”(HQ)和“黄褐斑”(Tri-Luma®)。许多非HQ的提亮/美白剂,包括抗氧化剂和植物性药妆品,最近充斥市场,宣称具有较低的刺激性潜力,并避免了与HQ制剂相关的不良影响,如致癌和皮肤褐黄病。将局部治疗与化学剥脱、强脉冲光(IPL)、非剥脱性分次激光或射频、色素激光(微秒、皮秒、Q开关)和微针等手术相结合,可提高效果。通过适当治疗,黄褐斑可以得到控制、改善和维持;另外,大多数情况下PIH可以治愈。在此,我们综述这两种情况的治疗方法,并就如何进行适当管理以提高效果提出意见。